Cell Cryopreservation Market By Product Type (Cryopreservation Media, Cryopreservation Equipment, Cryogenic Storage Systems, Consumables and Accessories), By Cell Type (Stem Cells, Immune Cells, Reproductive Cells, Tumor Cells, Other Cell Types), By Application (Regenerative Medicine, Cell-Based Research, Drug Discovery and Development, Biobanking, Fertility Preservation), By End User (Biotechnology and Pharmaceutical Companies, Research Institutes and Universities, Hospitals and Clinics, Biobanks and Cell Banks), By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Cell Cryopreservation Market: The Cold Chain Backbone Powering Cell-Based Medicine

The Global Cell Cryopreservation Market was valued at USD 10.20 billion in 2025 and is projected to reach USD 18.05 billion by 2032, expanding at a CAGR of 8.5% during 2026–2032.

 

Cell cryopreservation, the process of preserving living cells at ultra-low temperatures to halt all biological activity while maintaining viability for future use, has moved from a routine laboratory practice to a revenue-critical part of cell therapy manufacturing, fertility treatment, stem-cell transplantation, biological research, and long-term sample banking.

 

Cell cryopreservation media and agents such as DMSO and glycerol are widely used to protect cells during freezing by reducing ice formation and preventing cell damage. They work by lowering the freezing point, controlling dehydration, and helping cells survive both freezing and thawing while maintaining membrane stability and post-thaw viability.

 

From a regulatory standpoint, these agents fall under the FDA’s 21 CFR Part 1271 framework for human cells, tissues, and cellular and tissue-based products (HCT/Ps). In clinical and commercial use—such as stem cell banking, reproductive medicine, and cell and gene therapy manufacturing—they must meet cGMP requirements to ensure sterility, consistency, and reliable post-thaw performance.

 

Mapping the Cell Cryopreservation Market: Media, Equipment, Storage & Consumables

Cryopreservation Media accounted for 31.0% of the market in 2025, representing USD 3.16 billion. The segment is projected to reach USD 5.78 billion and account for 32.0% of the market by 2032, expanding at a CAGR of 9.0%. Its leading position reflects the recurring use of preservation formulations in cell banking, research, assisted reproduction, and cell therapy manufacturing.

 

Cryopreservation Equipment represented 26.0% of the market in 2025, valued at USD 2.65 billion. The segment is projected to reach USD 4.51 billion by 2032, when its market share is expected to moderate to 25.0%. It is forecast to expand at a CAGR of 7.9%, supported by demand for controlled-rate freezers, automated freezing platforms, thawing devices, temperature-monitoring equipment, and laboratory-scale preservation systems.

 

Cryogenic Storage Systems held a 25.0% market share in 2025, equivalent to USD 2.55 billion. The segment is projected to reach USD 4.69 billion and increase its market share to 26.0% by 2032, registering the fastest product-type CAGR of 9.1%. Growth is associated with expanding long-duration storage requirements across cell therapy manufacturing, biobanks, fertility clinics, research repositories, and transplant programs.

 

Consumables and Accessories accounted for 18.0% of the market in 2025, representing USD 1.84 billion. The segment is projected to reach USD 3.07 billion by 2032, with its share easing to 17.0% and revenue expanding at a CAGR of 7.6%. Demand includes cryogenic vials, bags, straws, labels, racks, boxes, personal protective equipment, transfer components, and other materials used during freezing, storage, retrieval, and transportation.

 

Cell Lineage Segmentation: Mapping Demand Across Biological Cell Types

Stem Cells represented the largest cell-type segment in 2025, accounting for 34.0% of the market and USD 3.47 billion in revenue. The segment is projected to reach USD 6.50 billion by 2032, increasing its share to 36.0% and expanding at a CAGR of 9.4%. Growth is supported by hematopoietic stem-cell banking, regenerative medicine, induced pluripotent stem-cell research, mesenchymal stem-cell development, and cell therapy manufacturing.

 

Immune Cells held 24.0% of the market in 2025, valued at USD 2.45 billion. The segment is projected to reach USD 4.69 billion and account for 26.0% of the market by 2032. With a CAGR of 9.7%, immune cells represent the fastest-growing cell-type category, reflecting increasing preservation requirements for T cells, natural killer cells, dendritic cells, and other immune-cell populations used in research and therapeutic development.

 

Reproductive Cells accounted for 18.0% of the market in 2025, representing USD 1.84 billion. The segment is projected to reach USD 2.89 billion by 2032, while its market share is expected to decline to 16.0%. Its CAGR of 6.7% reflects continued demand for sperm, oocyte, and embryo preservation, although faster growth in regenerative medicine and immune-cell applications will reduce its relative market position.

 

Tumor Cells represented 14.0% of the market in 2025, valued at USD 1.43 billion. The segment is projected to reach USD 2.35 billion by 2032, accounting for 13.0% of the market and expanding at a CAGR of 7.4%. Demand is linked to oncology research, tumor biobanks, patient-derived models, biomarker studies, drug screening, and precision medicine programs.

 

Other Cell Types accounted for 10.0% of the market in 2025, equivalent to USD 1.02 billion. The segment is projected to reach USD 1.62 billion by 2032, with its market share declining to 9.0% and revenue growing at a CAGR of 6.9%. This category includes primary cells, microbial cells, hybridomas, specialized research cells, and other cellular materials not classified within the leading cell groups.

 

By Application and Emerging Use-Case Landscape

Regenerative Medicine represented the largest application segment in 2025, accounting for 28.0% of the market and USD 2.86 billion in revenue. It is projected to reach USD 5.60 billion and increase its share to 31.0% by 2032. The segment is forecast to expand at the fastest application CAGR of 10.1%, supported by the growing use of preserved stem cells, immune cells, engineered cells, and cell banks in advanced therapeutic development.

 

Cell-Based Research held 22.0% of the market in 2025, valued at USD 2.24 billion. The segment is projected to reach USD 3.79 billion by 2032, when it is expected to account for 21.0% of the market. Its CAGR of 7.8% reflects continuing demand from academic laboratories, research institutes, disease-model repositories, translational research programs, and biological resource centres.

 

Drug Discovery and Development accounted for 20.0% of the market in 2025, representing USD 2.04 billion. The segment is projected to reach USD 3.79 billion by 2032, increasing its share to 21.0% and expanding at a CAGR of 9.3%. Pharmaceutical and biotechnology companies use cryopreserved cells in screening, toxicity assessment, target validation, disease modelling, assay development, and preclinical research.

 

Biobanking represented 18.0% of the market in 2025, valued at USD 1.84 billion. The segment is projected to reach USD 3.07 billion by 2032, with its share easing to 17.0% and revenue expanding at a CAGR of 7.6%. Growth is associated with population biobanks, hospital repositories, public cord-blood programs, research collections, disease-specific banks, and commercial sample-storage services.

 

Fertility Preservation accounted for 12.0% of the market in 2025, representing USD 1.22 billion. The segment is projected to reach USD 1.81 billion by 2032, while its market share is expected to decline to 10.0%. Its CAGR of 5.7% reflects continued growth in egg, sperm, and embryo freezing, although regenerative medicine and drug-development applications are expanding more rapidly.

 

By End-User Ecosystem

Biotechnology and Pharmaceutical Companies represented the largest end-user segment in 2025, accounting for 37.0% of the market and USD 3.77 billion in revenue. The segment is projected to reach USD 7.22 billion and increase its market share to 40.0% by 2032. Its CAGR of 9.7% is the fastest among end users, reflecting expanding demand for cell banks, preservation media, controlled freezing, biostorage, and logistics across research, clinical development, and commercial manufacturing.

 

Research Institutes and Universities held 25.0% of the market in 2025, valued at USD 2.55 billion. The segment is projected to reach USD 4.33 billion by 2032, accounting for 24.0% of the market and expanding at a CAGR of 7.9%. Demand is supported by basic research, translational programs, stem-cell laboratories, university biobanks, disease modelling, and collaborative cell repositories.

 

Hospitals and Clinics accounted for 21.0% of the market in 2025, representing USD 2.14 billion. The segment is projected to reach USD 3.61 billion by 2032, with its market share declining slightly to 20.0% and revenue growing at a CAGR of 7.7%. Hospitals and clinics use cryopreservation infrastructure in fertility treatment, transplantation, oncology, regenerative medicine, pathology, and clinical research.

 

Biobanks and Cell Banks represented 17.0% of the market in 2025, valued at USD 1.73 billion. The segment is projected to reach USD 2.89 billion by 2032, accounting for 16.0% of the market and expanding at a CAGR of 7.6%. Spending is directed toward repository expansion, sample-processing systems, automated storage, consumables, monitoring platforms, inventory software, backup capacity, and long-term maintenance.

 

Fertility Treatment Is Expanding Long-Term Demand for Frozen Cell and Embryo Storage

Assisted reproductive technology is one of the largest recurring sources of cryopreservation activity. U.S. fertility clinics reported 435,426 assisted reproductive technology cycles involving 251,542 patients in 2022. Of the reported cycles, 184,423 were egg- or embryo-banking cycles in which all resulting eggs or embryos were frozen for future use. The National ART Surveillance System covers approximately 98% of ART cycles performed in the United States, making the data a strong indicator of the operational scale supported by fertility cryopreservation.

The UK fertility market shows growing reliance on frozen treatment pathways. In 2024, around 64,000 patients underwent over 100,000 IVF and freezing cycles under HFEA-licensed clinics. Frozen embryo transfers made up 48% of IVF cycles, up from 24% in 2014, while egg freezing activity rose sharply from about 700 patients in 2014 to 5,580 in 2024.

This expansion drives demand for cryopreservation media, storage tanks, consumables, monitoring systems, and long-term sample management services, creating recurring revenue from ongoing storage and handling.

However, it also increases operational risk. UK clinics reported 792 incidents in 2024/25, a 36% rise year-on-year, alongside 131 regulatory non-compliances, highlighting the importance of strict compliance, consent tracking, and storage controls in fertility cryopreservation services.

 

Cord-Blood Inventories Create Public Procurement and Recurring Banking Revenue

Public cord-blood programs create demand for collection, testing, processing, cryopreservation, storage, quality assurance, database management, and distribution. The U.S. C.W. Bill Young Cell Transplantation Program registry contained more than 247,900 available cord-blood units in February 2026. More than 121,000 were National Cord Blood Inventory units, and 3,900 NCBI units were added during 2025.

HRSA contracts with five public cord-blood banks to collect and maintain high-quality, genetically varied units. The agency awarded USD 15.8 million to contracted banks in 2025, following USD 16.5 million in 2024. HRSA gives priority to banks with FDA biological licences and demonstrated capability to collect genetically varied units, linking procurement opportunities to regulatory readiness, collection reach, and inventory quality.

Public cord-blood banking operates differently from private family banking because public banks must cover collection and testing costs even when many units are later rejected due to low cell count, contamination, or donor eligibility issues. As a result, government funding is essential to maintain inventory diversity and ensure enough usable units are available for transplantation.

In the U.S., the House-engrossed H.R. 5160 (July 2026) proposes reauthorizing the cord-blood inventory program through 2031 and allocating about USD 33 million annually to the C.W. Bill Young Cell Transplantation Program, although this remains proposed funding.

Japan also maintains a large public system, with the Japanese Red Cross reporting 10,914 searchable cord-blood units across six banks as of July 2026, highlighting sustained demand for cryogenic storage and transplant matching infrastructure.

Private banking generates recurring revenue through long-term storage fees after the initial preservation event. Cryo-Cell International reported USD 31.6 million in fiscal 2025 revenue, with USD 31.4 million coming from processing and storage services. This highlights the importance of ongoing storage income, although demand is influenced by birth rates, pricing, competition, and consumer awareness of future medical use.

 

Cell and Gene Therapy Is Raising the Commercial Value of Qualified Preservation Media

Cell and gene therapy manufacturing increases the value of preservation products because cells can be frozen at several stages of the production and delivery pathway. These stages may include master and working cell-bank creation, intermediate processing, final drug-product storage, clinical-site distribution, and preparation for administration.

A preservation failure at this level can delay treatment, invalidate a batch, interrupt a clinical trial, or require the recollection of patient material. Suppliers are therefore being evaluated on batch consistency, regulatory documentation, animal-component-free formulations, closed-system compatibility, scalability, post-thaw recovery, and integration with commercial manufacturing processes.

Regulatory development is also focusing on reducing reliance on traditional DMSO-based freezing solutions. The U.S. FDA has cleared PRIME-XV FreezIS DMSO-Free MD for use in processing human tissues and cells outside the body. According to the approval, this solution is designed to keep cells alive and maintain stem-cell quality after freezing, even when stored at very low temperatures ranging from −80°C to −196°C, without using DMSO. While DMSO is still widely used in cryopreservation, this approval shows a growing demand for safer and simpler alternatives, especially in cases where DMSO may cause toxicity, require extra removal steps, or complicate the overall process.

BioLife Solutions reported first-quarter 2026 revenue of USD 27.5 million, an increase of 25% from the same period in 2025, with a GAAP gross margin of 64%. The margin profile reflects the value attached to specialized preservation media and cell-processing consumables once they become embedded in validated clinical and commercial workflows.

Cryoport reported first-quarter 2026 revenue of USD 47.8 million, up 16% year over year. Life Sciences Services revenue increased 18% to USD 26.9 million, while BioStorage and BioServices revenue increased 21% to USD 5.2 million. The results show that preservation demand is being monetized through a combination of products, logistics, storage, documentation, and outsourced operational services.

 

Research Biobanks Are Turning Frozen Samples into Searchable Biological Assets

Research biobanks expand the market by converting biological samples into structured resources that can be located, qualified, retrieved, and distributed. UK Biobank holds approximately 17 million containers of blood, urine, and saliva samples. Around 11 million samples are maintained at its principal laboratory, including approximately 10 million in an automated −80°C freezer capable of retrieving about 250,000 samples annually. Its planned infrastructure includes capacity for up to 20 million samples and faster robotic retrieval.

These facilities create procurement opportunities for automated storage, robotics, cryogenic consumables, laboratory information-management systems, backup archives, temperature monitoring, sample retrieval, relabelling, data integration, and disaster-recovery services. The commercial value of a stored sample depends not only on viability but also on whether the associated consent, provenance, clinical data, processing history, and access restrictions can be verified.

BBMRI-ERIC’s Common Service IT illustrates this shift toward searchable infrastructure. Its directory covers nearly 700 biobanks, more than 2,500 sample and data collections, and an estimated inventory exceeding 100 million samples. Its digital services support sample discovery, access negotiation, quality information, interoperability, provenance, and legal compliance.

The European Bank for induced Pluripotent Stem Cells (EBiSC) shows how frozen cells can be turned into standardized products that can be shared and used by researchers around the world. Before releasing any iPSC (induced pluripotent stem cell) line, EBiSC carefully tests the cells to make sure they are safe and of high quality. These tests check for contamination (such as bacteria or viruses), correct cell identity, cell survival after freezing, normal cell structure, and whether the cells can still behave like stem cells.

The cells are usually frozen using a special protective solution called DMSO-based media, and each storage vial contains about one to two million cells. The cost to obtain a standard iPSC line is about £1,442 per vial, while more advanced gene-edited cell lines cost around £1,751 per vial.

 

Regulation Is Making Traceability and Process Control Competitive Requirements

U.S. establishments manufacturing human cells, tissues, and cellular and tissue-based products regulated under Section 361 of the Public Health Service Act must register with the FDA under 21 CFR Part 1271 within five days of starting operations and update annually. Foreign suppliers importing these products into the U.S. are also required to register.

However, registration does not equal FDA approval. Companies must still maintain quality systems, validated equipment, controlled processes, traceable records, and compliant handling procedures to meet regulatory expectations.

Cryopreservation outcomes also vary significantly by cell type, with different recovery rates seen across cord-blood cells, immune cells, iPSCs, and reproductive or mesenchymal cells. Key factors such as cooling rate, cryoprotectant use, and thawing conditions directly impact viability.

This has increased demand for standardized, application-specific solutions, including DMSO-free or reduced-DMSO media, automated freezing systems, and validated protocols, with suppliers increasingly competing on regulatory support and process consistency.

 

Cryopreservation Protocol Optimization Is Driving Demand for Advanced Preservation Technologies

The growth of the cell cryopreservation industry is increasingly linked to improvements in preservation protocols rather than only the availability of storage technologies. As cell-based research, regenerative medicine, immunotherapy, and cell and gene therapy programs expand, maintaining cellular integrity from collection to long-term storage has become a critical requirement. Cryopreservation protocols are evolving from basic freezing approaches into highly controlled workflows involving optimized cryoprotective formulations, controlled cooling systems, validated storage conditions, and standardized recovery procedures. This transition is expected to accelerate demand for advanced cryopreservation media, automated freezing equipment, cryogenic storage systems, and monitoring solutions.

A typical cell cryopreservation workflow involves harvesting healthy cells, preparing them with appropriate freezing media, controlled reduction of temperature, storage under cryogenic conditions, and subsequent thawing with minimal loss of viability. The success of this process depends on multiple parameters, including cell type, growth phase, cell concentration, freezing rate, cryoprotectant composition, and storage stability.

The requirement for reproducible outcomes is increasing the adoption of specialized cryopreservation products instead of traditional laboratory-prepared freezing solutions. Research laboratories and commercial cell therapy manufacturers are increasingly shifting toward ready-to-use, chemically defined, and GMP-compatible preservation media to reduce variability and improve batch-to-batch consistency. This trend is creating opportunities for manufacturers of advanced cryopreservation reagents and cell preservation formulations.

Cryoprotective agents (CPAs) represent a core component of the cryopreservation process as they protect cells from damage caused by ice crystal formation and osmotic stress during freezing. Dimethyl sulfoxide (DMSO) remains one of the most widely used cryoprotectants, while glycerol and newer DMSO-reduced or DMSO-free formulations are being explored for sensitive applications.

The increasing use of stem cells, immune cells, and genetically modified therapeutic cells is generating demand for application-specific cryopreservation formulations. Different cell populations demonstrate varying tolerance to freezing conditions; therefore, universal freezing solutions are gradually being replaced by customized preservation media designed for specific cell types such as hematopoietic cells, mesenchymal stem cells, pluripotent stem cells, and immune cells. This shift supports market growth for specialized cryopreservation reagents and validated preservation platforms.

Temperature management during freezing is a major factor affecting post-thaw cell survival. Controlled-rate freezing, commonly involving gradual cooling before transfer to long-term cryogenic storage, helps reduce cellular stress and improves recovery outcomes. Traditional manual freezing methods using passive cooling containers remain widely used; however, increasing regulatory requirements and the need for reproducibility are driving adoption of programmable controlled-rate freezers and automated cryopreservation systems.

The expansion of cell therapy manufacturing is expected to further increase demand for automated freezing technologies because commercial-scale production requires consistent processing across thousands of samples. Automation also supports compliance with quality standards by reducing operator-dependent variation during critical freezing steps.

Long-term preservation requires storage of cryogenic vials under ultra-low temperature conditions, typically in liquid nitrogen environments. Maintaining temperature stability, preventing contamination, and ensuring accurate sample identification have become essential considerations for research institutions, biobanks, and therapeutic manufacturers.

The increasing establishment of cell banks, including master cell banks, working cell banks, stem cell repositories, and clinical-grade cell storage facilities, is driving demand for high-capacity cryogenic storage systems, specialized cryogenic containers, monitoring devices, and inventory management solutions. Proper labeling, digital tracking, and documentation practices are becoming increasingly important as organizations manage larger collections of valuable biological materials.

Successful cryopreservation depends not only on freezing technology but also on upstream and downstream quality control practices. Before freezing, cells must demonstrate appropriate health status, adequate growth conditions, and absence of contamination. Following thawing, evaluation of viability, recovery rate, functionality, and genetic stability is necessary to confirm preservation success.

The growing focus on quality assurance in cell-based therapies is encouraging organizations to adopt validated cryopreservation workflows supported by standardized testing protocols. As regulatory expectations increase, demand is shifting toward integrated solutions combining preservation media, freezing equipment, storage systems, monitoring technologies, and validation services.

One of the major trends shaping the future cell cryopreservation market is the movement toward customized protocols for different biological materials. Stem cells, immune cells, primary cells, organoids, and engineered therapeutic cells exhibit unique freezing and recovery characteristics, requiring tailored preservation strategies.

For example, pluripotent stem cells require specialized handling approaches to maintain differentiation potential and genetic stability, while immune cells used in advanced therapies require preservation methods that maintain functional activity after thawing. The increasing diversity of cell-based applications is therefore expanding the market beyond conventional cell line storage toward specialized cryopreservation solutions designed for individual therapeutic and research applications.

Future growth in the cell cryopreservation market will be influenced by advancements in protocol optimization, automation, and quality-controlled preservation systems. As cell therapies move from research laboratories toward commercial manufacturing, the ability to preserve cells with high viability, functionality, and consistency will become a key competitive factor.

Consequently, innovations in cryoprotective media, controlled-rate freezing technologies, automated thawing platforms, cryogenic monitoring systems, and digital sample management are expected to create new revenue opportunities across the cryopreservation ecosystem. Companies that can provide reliable, scalable, and application-specific preservation solutions are likely to benefit from increasing demand from biotechnology companies, pharmaceutical developers, academic institutions, and biobanking organizations.

 

Regional Analysis: North America Retains Market Leadership as Asia Pacific Accelerates

North America represented the largest Cell Cryopreservation Market in 2025, accounting for 39.0% of global revenue and USD 3.98 billion. The regional market is projected to reach USD 6.68 billion by 2032, expanding at a CAGR of 7.7%, although its global share is expected to moderate to 37.0%. The region benefits from established cell and gene therapy manufacturing, high assisted reproductive technology volumes, federally supported cord-blood programs, private cell banking, and a concentrated base of biopreservation, sample-management, and cold-chain companies. U.S. fertility activity and HRSA-supported cord-blood inventories create recurring demand for preservation media, storage systems, monitoring platforms, consumables, and qualified logistics.

Europe held 27.0% of the global market in 2025, representing USD 2.75 billion. The market is projected to reach USD 4.69 billion by 2032, accounting for 26.0% of global revenue and expanding at a CAGR of 7.9%. Regional demand is supported by regulated fertility services, population biobanks, academic repositories, pharmaceutical research, and cross-border biological sample networks. The HFEA-regulated fertility sector, UK Biobank, BBMRI-ERIC, and EBiSC illustrate Europe’s investment in long-term sample storage, automated retrieval, cell-line quality control, and digital sample-access infrastructure.

Asia Pacific accounted for 24.0% of the Cell Cryopreservation Market in 2025, valued at USD 2.45 billion. It is projected to reach USD 4.87 billion and increase its global share to 27.0% by 2032. With a CAGR of 10.3%, Asia Pacific is the fastest-growing regional market. Expansion is associated with regenerative medicine research, fertility-treatment networks, public cord-blood banking, biopharmaceutical manufacturing, hospital modernization, and investment in local cell therapy capabilities. Japan’s public cord-blood infrastructure demonstrates established institutional demand, while broader regional growth will depend on regulatory development, domestic production of preservation products, and access to qualified cryogenic facilities.

Latin America represented 6.0% of the global market in 2025, equivalent to USD 0.61 billion, and is projected to reach USD 1.08 billion by 2032 at a CAGR of 8.5%. Its market share is expected to remain at 6.0%. Commercial activity is concentrated in private fertility clinics, cord-blood banks, hospital laboratories, academic institutions, and selected biopharmaceutical research centres. Growth remains sensitive to imported equipment and consumable costs, specialist workforce availability, liquid-nitrogen infrastructure, and the development of national biobanking standards.

The Middle East and Africa accounted for 4.0% of the market in 2025, representing USD 0.41 billion. The regional market is projected to reach USD 0.72 billion by 2032, maintaining a 4.0% share and expanding at a CAGR of 8.5%. Opportunities are concentrated in specialized fertility centres, private hospital networks, transplantation programs, research institutions, and government-supported biobanking initiatives. Market expansion is likely to remain uneven because advanced storage infrastructure and regulated cell-processing capacity are concentrated in a limited number of countries and major healthcare centres.

Regional competition will increasingly reflect infrastructure depth rather than sample demand alone. North America retains an advantage through commercial cell therapy activity and integrated service providers, while Europe is differentiated by coordinated research repositories and regulatory oversight. Asia Pacific offers the strongest expansion potential as cell research, fertility treatment, and biopharmaceutical manufacturing scale. Latin America and the Middle East and Africa will provide selective opportunities for suppliers using local distribution, centralized biostorage, institutional partnerships, and service-based market entry models.

 

Competitive Landscape: Media, Storage and Logistics Platforms Are Converging

Competition in the Cell Cryopreservation Market includes media suppliers, equipment makers, storage providers, and cold-chain logistics firms, but boundaries are blurring as companies move toward full workflow solutions.

Key players are expanding integrated offerings. BioLife Solutions focuses on biopreservation media and cell-processing tools for cell and gene therapy. Cryoport provides end-to-end logistics, biostorage, monitoring, and support services. Azenta combines automated storage systems, cryogenic equipment, consumables, and digital sample management, while Cryo-Cell operates a model based on processing fees plus long-term storage revenue.

Azenta’s Sample Management Solutions segment generated USD 81 million in Q2 FY2026 (up 2% YoY) and USD 88 million in Q3 FY2026 (up 14%), supported by repository services and consumables, showing steady growth in storage-driven revenue streams.

Consolidation is also increasing. In July 2026, Repligen agreed to acquire BioLife Solutions for about USD 1.5 billion, strengthening its position in bioprocessing and cell preservation technologies, with completion expected in Q4 2026 pending approvals.

Overall, competition is shifting toward integrated platforms, where success depends on validated cell recovery, recurring revenue models, regulatory compliance, global service reach, and digital tracking systems, rather than standalone equipment or reagents.

 

Analyst View: Recurring Revenue and Workflow Integration Will Define Market Leadership

The Cell Cryopreservation Market is moving away from equipment-only sales toward full biological sample management. While freezers and liquid-nitrogen systems remain essential, more value is now generated from consumables, storage services, monitoring tools, software, logistics, and compliance documentation.

Demand is driven by fertility clinics, biobanks, transplant programs, and cell therapy manufacturers. Once a system or storage provider is validated in a regulated workflow, switching becomes difficult due to requalification, training, and compliance requirements. This supports long-term contracts and recurring revenue.

Consumables like cryopreservation media and reagents remain important because they are used in every freezing cycle and often integrated into manufacturing processes. Storage and biobanking services also generate multi-year income, while logistics providers benefit from the movement of samples between clinics, labs, and manufacturing sites.

 

Cell Cryopreservation Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 10.20 Billion
Revenue Forecast in 2032	USD 18.05 Billion
Overall Growth Rate	CAGR of 8.5% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Cell Type, By Application, By End User, By Geography
By Product Type	Cryopreservation Media, Cryopreservation Equipment, Cryogenic Storage Systems, Consumables and Accessories
By Cell Type	Stem Cells, Immune Cells, Reproductive Cells, Tumor Cells, Other Cell Types
By Application	Regenerative Medicine, Cell-Based Research, Drug Discovery and Development, Biobanking, Fertility Preservation
By End User	Biotechnology and Pharmaceutical Companies, Research Institutes and Universities, Hospitals and Clinics, Biobanks and Cell Banks
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising cell and gene therapy manufacturing, expansion of fertility preservation services, growing biobanking infrastructure, increasing demand for long-term biological sample storage and regulatory-compliant preservation workflows
Customization Option	Available upon request